Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Washington
Fred Hutchinson Cancer Center
Mayo Clinic
City of Hope Medical Center
City of Hope Medical Center
University of Washington
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Mayo Clinic
City of Hope Medical Center
City of Hope Medical Center
Roswell Park Cancer Institute
City of Hope Medical Center
University of Washington